ADC Therapeutics ( ($ADCT) ) just unveiled an announcement. On September 30, 2025, ADC Therapeutics released an updated corporate presentation ...
Late-breaking data from IDeate-Lung01 phase 2 trial demonstrate potential of ifinatamab deruxtecan to become first-in-class B7-H3 directed ADC for pretreated extensive-stage small cell lung cancer ...